Coefficient of Variation in Metastatic Lymph Nodes Determined by 18F-FDG PET/CT in Patients with Advanced NSCLC: Combination with Coefficient of Variation in Primary Tumors

被引:5
作者
Pellegrino, Sara [1 ]
Fonti, Rosa [1 ]
Vallone, Carlo [1 ]
Morra, Rocco [2 ]
Matano, Elide [2 ]
De Placido, Sabino [2 ]
Del Vecchio, Silvana [1 ]
机构
[1] Univ Naples Federico II, Dept Adv Biomed Sci, I-80131 Naples, Italy
[2] Univ Naples Federico II, Dept Clin Med & Surg, I-80131 Naples, Italy
关键词
non-small cell lung cancer; F-18-FDG PET/CT; coefficient of variation; heterogeneity of glycolytic phenotype; prognosis; CELL LUNG-CANCER; HETEROGENEITY ANALYSIS; PARAMETERS;
D O I
10.3390/cancers16020279
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The aim of the present study was to test whether the coefficient of variation (CoV) of F-18-FDG PET/CT images of metastatic lymph nodes and primary tumors may predict clinical outcome in patients with advanced non-small cell lung cancer (NSCLC). Materials and Methods Fifty-eight NSCLC patients who had undergone F-18-FDG PET/CT at diagnosis were evaluated. SUVmax, SUVmean, CoV, MTV and TLG were determined in targeted lymph nodes and corresponding primary tumors along with Total MTV (MTVTOT) and Whole-Body TLG (TLG(WB)) of all malignant lesions. Univariate analysis was performed using Cox proportional hazards regression whereas the Kaplan-Meier method and log-rank tests were used for survival analysis. Results Fifty-eight metastatic lymph nodes were analyzed and average values of SUVmax, SUVmean, CoV, MTV and TLG were 11.89 +/- 8.54, 4.85 +/- 1.90, 0.37 +/- 0.16, 46.16 +/- 99.59 mL and 256.84 +/- 548.27 g, respectively, whereas in primary tumors they were 11.92 +/- 6.21, 5.47 +/- 2.34, 0.36 +/- 0.14, 48.03 +/- 64.45 mL and 285.21 +/- 397.95 g, respectively. At univariate analysis, overall survival (OS) was predicted by SUVmax (p = 0.0363), SUVmean (p = 0.0200) and CoV (p = 0.0139) of targeted lymph nodes as well as by CoV of primary tumors (p = 0.0173), MTVTOT (p = 0.0007), TLG(WB) (p = 0.0129) and stage (p = 0.0122). Using Kaplan-Meier analysis, OS was significantly better in patients with CoV of targeted lymph nodes <= 0.29 than those with CoV > 0.29 (p = 0.0147), meanwhile patients with CoV of primary tumors > 0.38 had a better prognosis compared to those with CoV <= 0.38 (p = 0.0137). Finally, we combined the CoV values of targeted lymph nodes and primary tumors in all possible arrangements and a statistically significant difference was found among the four survival curves (p = 0.0133). In particular, patients with CoV of targeted lymph nodes <= 0.29 and CoV of primary tumors > 0.38 had the best prognosis. Conclusions The CoV of targeted lymph nodes combined with the CoV of primary tumors can predict prognosis of NSCLC patients.
引用
收藏
页数:11
相关论文
共 30 条
[1]  
Anan N, 2022, INSIGHTS IMAGING, V13, DOI 10.1186/s13244-021-01153-9
[2]   Heterogeneity Analysis of 18F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting [J].
Budiawan H. ;
Cheon G.J. ;
Im H.-J. ;
Lee S.J. ;
Paeng J.C. ;
Kang K.W. ;
Chung J.-K. ;
Lee D.S. .
Nuclear Medicine and Molecular Imaging, 2013, 47 (4) :232-241
[3]   18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study [J].
Carvalho, Sara ;
Leijenaar, Ralph T. H. ;
Troost, Esther G. C. ;
van Timmeren, Janna E. ;
Oberije, Cary ;
van Elmpt, Wouter ;
de Geus-Oei, Lioe-Fee ;
Bussink, Johan ;
Lambin, Philippe .
PLOS ONE, 2018, 13 (03)
[4]   The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome [J].
Caswell, Deborah R. ;
Swanton, Charles .
BMC MEDICINE, 2017, 15
[5]   A systematic review of the prognostic value of texture analysis in 18F-FDG PET in lung cancer [J].
Han, Sangwon ;
Woo, Sungmin ;
Suh, Chong Hyun ;
Kim, Yeon Joo ;
Oh, Jungsu S. ;
Lee, Jong Jin .
ANNALS OF NUCLEAR MEDICINE, 2018, 32 (09) :602-610
[6]   Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [J].
Hendriks, L. E. ;
Kerr, K. M. ;
Menis, J. ;
Mok, T. S. ;
Nestle, U. ;
Passaro, A. ;
Peters, S. ;
Planchard, D. ;
Smit, E. F. ;
Solomon, B. J. ;
Veronesi, G. ;
Reck, M. .
ANNALS OF ONCOLOGY, 2023, 34 (04) :339-357
[7]  
Henriksson E, 2007, ANTICANCER RES, V27, P2155
[8]   The biology and management of non-small cell lung cancer [J].
Herbst, Roy S. ;
Morgensztern, Daniel ;
Boshoff, Chris .
NATURE, 2018, 553 (7689) :446-454
[9]   Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine [J].
Hiley, Crispin ;
de Bruin, Elza C. ;
McGranahan, Nicholas ;
Swanton, Charles .
GENOME BIOLOGY, 2014, 15 (08)
[10]   The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non-small cell lung cancer [J].
Hua, Jun ;
Li, Lan ;
Liu, Lisheng ;
Liu, Qi ;
Liu, Ying ;
Chen, Xiaoliang .
NUCLEAR MEDICINE COMMUNICATIONS, 2021, 42 (11) :1247-1253